LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) ...

CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made ...

CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, ...

CAR T cell therapy has transformed blood cancer treatment, but success in solid tumors remains limited by major challenges such as on-target/off-tumor toxicity, poor tumor infiltration, and an ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

Viruses are effective tools for delivering genetic material into cells, and scientists have taken advantage of viral transduction in numerous ways, such as constructing chimeric antigen receptor (CAR) ...